Select your Market
-
{{ userContent.title }}
{{ userContent.lookingForMoreLabel }}
Healthcare R&D
Our research scientists are working tirelessly to develop groundbreaking medicines and technologies to treat everything from cancer and multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more
Life Science R&D
R&D focus: Reimagining new ways to meet the needs of our customers
Innovation is at the core of the value that we deliver to our customers. Our Life Science scientists and engineers tirelessly work to develop novel approaches to new and age-old challenges.We show our commitment to innovation through our financial investments as well. Every year, we invest around €400 million in R&D, supporting new innovations designed to meet our customers' most unmet needs – from antibodies to water purification systems. Innovation is visible when new products hit the shelves and when new services emerge.
The ability to innovate is the core of our culture across all three of our businesses; Process Solutions, Advanced Solutions and Discover Solutions. Learn more
Electronics R&D
R&D focus: Keeping the world’s Electronics on the cutting edge
Our Electronics business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation ...
The Company announced that the FDA has granted Breakthrough Therapy designation to enpatoran
2026/07/08
-
Press Releases
2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos
The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.
2026/06/23
-
Information
AGM: Beckmann to be appointed as CEO May 1
Belén Garijo passed symbolically the baton to Kai Beckmann. Annual General Meeting approved dividend of € 2.20.
2026/04/24